Morning everybody. Uh my name is Jason Mles and I am the CEO of Sergeenics. So Sergeenics, so we're redefining early brain health through AIdriven So brain injury is a leading cause of death and long-term disability in term and pre-term infants and it affects at least five in a thousand newborns. The unfortunate reality, however, is that brain injury is being missed at birth. So why is brain injury being undetected? Well, there are a number of reasons for this. The first thing is it's often clinically invisible. So there's no outward signs. 50% of infants with cerebal palsy are not diagnosed in the newborn period. Secondly, EEG or electron which is the gold standard for assessing newborn brain function is simply not readily available. In fact, it's not available in over 80% of hospitals in the US and it's very similar scenario in Europe. There's a lot of reasons for this but the key reason is that EEG or electrophoggram uh which is the gold standard for assessing a brain function uh is not there there's a massive shortage of experts globally to review and interpret EEG. Okay. Um so in the absence of EEG what does the current standard of care look like? Well when a baby's born there's a lot of things going on. There's a lot happening. Uh but the first thing they do or one of the things they do is a routine APGAR score routine APGAR exam. uh then they look at um cord pH and they look at other um vital signs. They then assess based on that based on those surrogate measures is there a risk of brain injury? Is there a risk of brain injury present? If they believe there is if the physician believes there is they then go ahead and do a neurological exam uh or a sarna test. This is a highly subjective exam where they look at posture, tone, reflexes and so on and the results can have a high degree of variability. really what they're lacking, what the physician is lacking at this point is an objective and direct assessment of brain function. There are interventions available. One of the key interventions is therapeutic hypothermia or cooling. Um but that must be administered within six hours to be effective. So we have this critical time period to identify the newborns at risk of brain injury and then to uh intervene if and when appropriate. So what does that mean on a day-to-day basis for physicians? Well, it means physicians are often left with with, you know, reviewing infants like this little guy here, trying to determine subjectively if brain injury is present or not. The question they're continually asking themselves is, "Do I need to worry about this baby's brain?" The answer to that question can have lifelong consequences both for the newborn and for their and for the family. And indeed, it can have ramifications from a litigation perspective as well. So in summary, the current standard of care then is a mix of subjective judgment and limited technology. And in some cases, it feels like the best we can do is make an educated guess as to the presence of brain injury. So that's why we've developed surrogenics wave. Senenix wave delivers fast objective brain assessments with no specialist EG required. So [clears throat] we are importantly any clinician or health care profession can or healthare professional can be trained to use this in a matter of minutes. So we're very much an AI and software company. We're leveraging hardware that's already out in the market today that's C and FDA approved. Uh and it's a very simple test. We simply put four electrodes uh on the newborn uh which runs into a a twochannel EG amplifier and into a medical grade tablet. We take 10 minutes of EG that goes into the cloud. Uh that's where all our AI and inferencing takes place. Um we then [clears throat] within 10 or 15 seconds send a pass or fail type result back to the tablet and back to the health care professional to the user. We're looking for abnormal EEG patterns that are consistent with newborn brain injury. If we identify or find anything consistent with that, we send a fail back to to the tablet to the healthare professional. This product is designed as an adjunct. Uh it's a um it's a decision support tool. It provides additional evidence point to physicians to help them make a more informed decision regarding next steps. Importantly though and critically, it's a direct datadriven objective assessment of brain function in a matter of minutes that clinicians simply do not have available them today. So surge wave is part of our wider wave AI platform. We've got a waveet cloud portal there which allows online access and remote reviewing of the EEG. We have our API layer which allows connectivity and thirdarty uh collaborations. We have our data labeling system, our AI data engine. We've invested heavily in this and that allows us to rapidly annotate and label uh uh rapidly annotate and label um EEG and that indeed accelerates the production and development of our AI and all of that sits on a uh data management secure storage system um which is compliant with all hospital standards. So at this point in the journey, we have a lot of robust evidence to support what we've doing. We've met with over 200 health care professionals and we have [clears throat] um really validated the the unmet clinical need. We're also part of the FDA breakthrough device designation program. Uh and that's been been great for us as an external validation. The FDA through that program uh identify companies, you know, and support the unmet need um and help them through through the process. We've completed a feasibility study with 93 newborns um that's been very successful. We've proven end to end that the uh product works, the wave device works from application of the electrodes right through to the reading of the EG in the cloud. We're publishing our AI. So the AI that's in the cloud, there's a number of algorithms that are working there. We're publishing them individually. Our first paper is in nature digital journal and um we've proven that our seizure detection AI and neonates works expert human level. That's the first time that's been done before. We're kicking off our investigational studies in Europe and the US. And we're working now hard on our registry road map. um to get our FDA denovo submission and our CU submissions into uh into the regulatory bodies in Q1 next year. So hopefully within about 12 to 13 months we'll be regulatory approved and on the market in both Europe and the US. Our business model has a number of components. Our revenue model is driven by a SAS model which is a monthly subscription uh with a click charge per use. Our reimbursement model leverages in the US leverages existing DRG codes uh and bundle evaluation and monitoring codes. Um we're very much building on on decades of research here with surgeonics. My co-founder, Professor uh Gerilene Bolan is a professor of neonatal physiology. She's also the founder of the infant research center in University College Cork. Uh and that's a center dedicated to pregnancy, birth and early childhood. Uh Jar has, you know, 500 plus publications in this area. She spent a huge amount of time researching the neonatal brain uh and was at the forefront of early machine learning techniques. Uh we're a spin out from the infant center uh in UCCC and we have close ties with them. We also have a very strong globally recognized scientific advisory board in place who've been instrumental uh in supporting and driving us uh over the last couple of years in the development of the product. We see a huge opportunity for Suggenics Wave. Uh ultimately when we set out our goal and ambition was that this this product would be a screener. Uh it would be uh all newborns would have their brain tested very similar to the audio screening test or to hepick test. Uh that's a huge market. We see that at about 12 billion globally. that's benchmarked against the penetration of the audio screening market which about 38 39% in the US EU alone that's about 2 billion uh and then in the entry market for us in the US in uh EU is around uh 400 million we've invested heavily in our platform uh our platform can not only process EG but it can process any physiological signal so that allows us then to to you know process ECG respiratory vital signs produce multimodal uh products and um you know a whole of AI is that we have a pipeline of you know high impact commercially viable solutions that that we're capable of driving out in the short to near term. The landscape here is evolving rapidly. It's historically been you know very dominated by hardware ccentric uh kind of capex type models. the last number of years we've seen some big players coming in like uh Cereabel in the adult space um brain scopes you know become bio signals and they've really disrupted the market uh leveraging EEG uh along with you know very kind of uh forward-looking AI um we believe that there's there's an innovation gap in neonatal care and we believe Sugenics are ideally capitalized to uh to to capitalize on that uh high level milestones very focused on our FDA CE submissions in Q1 2020 uh six and then hopefully about 12 to 13 months from now uh in H226 we'll be regally approved. Um and lastly then we've raised about 9 and a half 10 million to date a combination of diluted and non-diluted funding we'll be looking to raise uh 10 million plus series A uh around the time of our regular approval about 12 months from now and that will be used to drive market entry evidence generation strategy uh our new product development and to drive out uh our team expansion to support all of that. Uh, thank you very much.